Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Non-Current Deffered Revenue (2021 - 2025)

Ascendis Pharma A's Non-Current Deffered Revenue history spans 3 years, with the latest figure at $6.4 million for Q4 2023.

  • For Q4 2023, Non-Current Deffered Revenue fell 55.86% year-over-year to $6.4 million; the TTM value through Dec 2023 reached $6.4 million, down 55.86%, while the annual FY2023 figure was $6.4 million, 57.04% down from the prior year.
  • Non-Current Deffered Revenue for Q4 2023 was $6.4 million at Ascendis Pharma A, down from $14.5 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $14.5 million in Q4 2022 and bottomed at $3.4 million in Q4 2021.
  • The 3-year median for Non-Current Deffered Revenue is $6.4 million (2023), against an average of $8.1 million.
  • The largest annual shift saw Non-Current Deffered Revenue skyrocketed 327.66% in 2022 before it plummeted 55.86% in 2023.
  • A 3-year view of Non-Current Deffered Revenue shows it stood at $3.4 million in 2021, then surged by 327.66% to $14.5 million in 2022, then tumbled by 55.86% to $6.4 million in 2023.
  • Per Business Quant, the three most recent readings for ASND's Non-Current Deffered Revenue are $6.4 million (Q4 2023), $14.5 million (Q4 2022), and $3.4 million (Q4 2021).